In recent years, an overwhelming body of clinical evidence has firmly established the HIV Undetectable = Untra...Read more
Luye Pharma has entered an agreement with AstraZeneca China, the terms of which grant AstraZeneca China exclus...Read more
US based company, Life Biosciences has announced the closing of a Series B financing round of $50 million...Read more
Additive Orthopaedics, LLC., the leader in 3D printed orthopaedic foot and ankle devices, announces that is ha...Read more
Even environmentally friendly and energy efficient ultra-low temperature freezers traditionally consume a larg...Read more
Health 4.0 boosts Asia MedTech, Bio-pharma in 2019
Asia is a region of stark contrasts, with approximately 4.5 billion people – some 60 per cent of the world’s population – living in countries with a rich diversity of economic, political, and demographic constituents. In the coming year Asia will become a major hub for MedTech and Bio-Pharma activities for both local as well multinational companies.
Biotech companies in the region are also actively partnering with leading global biopharmaceutical companies on both the R&D and commercial fronts. Asset-level partnership remains very active during 2019. According to McKinsey Asia has the potential to leapfrog in the digital-health segment. Asia has an opportunity to take the lead in developing big data/advanced analytics solutions and technology platforms, with the potential to contribute to the global healthcare ecosystem.